Study Protocol Use of Benzodiazepines and Risk of Hip/Femur Fracture

Total Page:16

File Type:pdf, Size:1020Kb

Study Protocol Use of Benzodiazepines and Risk of Hip/Femur Fracture WP2 Framework for pharmacoepidemiological studies WG1 Databases Study Protocol Use of benzodiazepines and risk of hip/femur fracture. A methodological comparison across data sources and epidemiological design. Version: Final Nov 14, 2011 with Amendment 1 approved 29 Feb 2012 PROTECT_WP2_Final Protocol_Benzo_HIP fracture_Nov14 2011Amend1_approved29Feb2012 Page 1 of 177 WG1 Drug AE group Name Role Francisco de Abajo 1, 2 Protocol Lead Luis Alberto García Rodríguez 3 Protocol Backup Ulrik Hesse 4 Protocol Reviewer Andrew Bate 5 Protocol Reviewer Saga Johanson 6 Protocol Reviewer Frank de Vries 7 Protocol Reviewer Marietta Rottenkolber 8 Database 1 (Bavaria) lead Joerg Hasford 8 Database 1 (Bavaria) backup Miguel Gil 2 Database 2 (Bifap) lead Consuelo Huerta 2 Database 2 (Bifap) backup Ulrik Hesse4 Database 3 (DKMA) lead Frank de Vries7 Database 3 (DKMA) backup Montserrat Miret 11 and Jeane Pimienta 12 Database 3 (GPRD) lead Arlene Gallagher/ Dan Dedman /Jenny Campbell 13 Database 3 (GPRD) backup Olaf Klungel 7 Database 4 (Mondriaan) lead Liset van Dijk 7, 9 Database 4 (Mondriaan) backup Yolanda Alvarez 10 Database 5 (THIN) lead Ana Ruigomez 3 Database 5 (THIN) backup Mark de Groot7 and Raymond Schlienger14 WG1 coleads Olaf Klungel7 and Robert Reynolds5 WP2 coleads 1 Universidad de Alcalá, Madrid, Spain 2 Agencia Espanola de Medicamentos y Productos Sanitarios, Madrid, Spain (AEMPS) 3 Fundación Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain (CEIFE) 4 Lægemiddelstyrelsen (Danish Medicines Agency), Copenhagen, Denmark (DKMA) 5 Pfizer Ltd, New York, USA (Pfizer) 6 AstraZeneca AB, Molndal, Sweden (AZ) 7 Universiteit Utrecht, Utrecht, The Netherlands (UU) 8 Ludwig‐Maximilians‐Universität‐München, Munich, Germany (LMU‐ Muenchen) 9 Netherlands Institute for Healthcare Research, Utrecht, The Netherlands (NIVEL) 10 European Medicines Agency, London, United Kingdom (EMA) 11 Merck KGaA, Geneva, Switzerland (ME) 12 GlaxoSmithKline Research and Development LTD, UK (GSK) 13 General Practice Research Database, London, United Kingdom (GPRD) 14 Novartis Pharma, Switzerland (Novartis) PROTECT_WP2_Final Protocol_Benzo_HIP fracture_Nov14 2011Amend1_approved29Feb2012 Page 2 of 177 Contents 1. Context of the studies ...................................................................................................................... 6 2. Background ....................................................................................................................................... 6 3. Objectives ......................................................................................................................................... 7 4. Methods ........................................................................................................................................... 7 4.1. Data Source ...................................................................................................................................... 7 4.1.1. Bavarian Claims Database (Germany) .......................................................................................... 7 4.1.2. BIFAP (Spain) ................................................................................................................................ 7 4.1.3. National Databases (Denmark) .................................................................................................... 7 4.1.4. General Practice Research Database (UK) ................................................................................... 8 4.1.5. Mondriaan (The Netherlands) ..................................................................................................... 9 4.1.6. The Health Improvement Network (UK) ...................................................................................... 9 4.2. Period of valid data collection .......................................................................................................... 9 4.2.1. GPRD /THIN/Mondriaan/BIFAP Databases .................................................................................. 9 4.2.2. Bavarian Claims Database .......................................................................................................... 10 5. Study Designs ................................................................................................................................. 10 5.1 Descriptive study ............................................................................................................................ 11 5.1.1 Study Population ............................................................................................................................ 11 5.1.2 Exposure description ...................................................................................................................... 12 5.1.3 Outcome description ...................................................................................................................... 15 5.2 Analytical studies ............................................................................................................................ 16 5.2.1 Study population ............................................................................................................................ 16 5.2.2 Outcome Definition ........................................................................................................................ 17 5.2.3 Exposure definition ........................................................................................................................ 18 5.2.4 Potential confounders .................................................................................................................... 20 5.2.5 Analysis ........................................................................................................................................... 20 5.3 Cohort study ................................................................................................................................... 21 5.3.1 Follow‐up ........................................................................................................................................ 21 5.3.2 Analysis ........................................................................................................................................... 21 5.4 Nested case‐control study .............................................................................................................. 22 5.4.1 Case definition ................................................................................................................................ 22 5.4.2 Selection of controls ....................................................................................................................... 22 5.4.3 Exposure definition ........................................................................................................................ 22 5.4.4 Analysis ........................................................................................................................................... 22 5.5 Case‐crossover analysis .................................................................................................................. 23 5.5.1 Study population ............................................................................................................................ 23 5.5.2 Analysis ........................................................................................................................................... 23 5.6 Self‐controlled case series analysis ................................................................................................ 23 5.6.1 Study population ............................................................................................................................ 23 5.6.2 Analysis ........................................................................................................................................... 24 6. Instrumental variable analysis........................................................................................................ 24 7. Limitations ...................................................................................................................................... 25 8. References ...................................................................................................................................... 27 9 Annexes .......................................................................................................................................... 30 9.1 Annex I Codes for exposure and outcome ..................................................................................... 30 9.2 Annex II Codes for benzodiazepines indication ............................................................................. 36 9.3 Annex III Codes for potential confounders .................................................................................... 56 9.3.1 Codes for group b) Well established risk factors for fracture ........................................................ 56 9.3.2 Codes for group c) Risk factors immediately related to the outcome ........................................... 85 9.3.3 Codes for group d) Other risk factors that have been associated with fracture in the past. ........ 88 PROTECT_WP2_Final Protocol_Benzo_HIP fracture_Nov14 2011Amend1_approved29Feb2012 Page 3 of 177 10. APPENDIX (Amendments) ............................................................................................................ 173
Recommended publications
  • Pancreas-Neuroendocrine-Tumors-An-Introduction.Pdf
    JOP. J Pancreas (Online) 2018 Dec 31; S(3):321-327. REVIEW ARTICLE PANCREATIC NEUROENDOCRINE TUMORS Pancreas Neuroendocrine Tumors: An Introduction Yasunaru Sakuma, Naohiro Sata, Alan Kawarai Lefor Department of Gastroenterological Surgery, Jichi Medical University, Tochigi, Japan ABSTRACT Neuroendocrine tumors are rare, however their incidence is increasing. Details of the clinical aspects of these unusual tumors are gradually being revealed all over the world. Pancreas neuroendocrine tumors are a heterogeneous group of tumors with diverse morphologies and behaviors. However, as their character is being revealed, new treatment options have been developed in recent years. This introduction presents an overview of Pancreas Neuroendocrine Tumors, with a focus on their origin, character, epidemiology and biology. Origin of Neuroendocrine Tumors of the Pancreas also throughout the body as if supporting the DNES concept, and are thought to originate in the embryologic “Neuroendocrine tumors (NET)” are considered to neural crest [4]. This APUD cell concept cleverly arise from "neuroendocrine cells" located in various explains the origin of Multiple Endocrine Neoplasms parts of the body. Since neuroendocrine cells are located (MEN) which produce multiple peptide hormone, and throughout the body, these tumors can originate in many synchronous and/or metachronous tumors which occur organs of the body including the pancreas, gastrointestinal also in multiple organs. While the pituitary and adrenal tract, lung, etc. [1]. The origin of the cells from which glands, target organs for MEN, are known to be derived neuroendocrine tumor cells arise is not well understood. from ectodermal tissue, the pancreas is originally from However, neuroendocrine cells can be divided into two endoderm.
    [Show full text]
  • South Carolina Central Cancer Registry 2021 Data Reporting Requirements & Guidelines
    South Carolina Central Cancer Registry 2021 Data Reporting Requirements & Guidelines NAACCR Version 21 Record Layout and Data Standard Recommendations Revised 01/11/2021 Please visit SCCCR DHEC Website for Cancer Standards and Reporting, Education and Resources: https://scdhec.gov/CancerRegistry NOTE: This document does not replace the SCCCR REPORTING SOURCE MANUAL. This document should be used in conjunction with it. This document may re-state some of its content and is specifically meant for 2021 reporting guidance. Recent updated 01/11/2021 highlighted in yellow 1 PREFACE Important Notice to South Carolina Registrars Regarding Abstracting and Reporting 2021 Diagnosed Cases Prior to Release of NAACCRv21 Compliant Software. The extensive changes for 2021 include twenty-six new data items, twenty-five revised items, and eighteen retired reserved data items. Additionally, we will be adopting the implementation of ICD-O-3.2 as well as the 2021 revisions to the Site-Specific Prognostic Data Items, Solid Tumor Rules, 2018 SEER Summary Stage, 2018 SEER EOD, 2018 SEER Grade Manuals, as well as the Commission on Cancer’s STORE Manual (formerly named FORDS). All the 2021 data changes are requirements from national standard setting agencies and were not initiated by the South Carolina Central Cancer Registry. Reporting facilities in South Carolina should direct any corrections, comments, and suggestions regarding this document to Connie Boone ([email protected]). If individuals or facilities that are not part of the South Carolina reporting system need copies of the reporting manual, they may download the PDF from the South Carolina Central Cancer Registry website: https://scdhec.gov/health-professionals/electronic-health- records-meaningful-use/cancer-registry-data-standards To open PDF click on the SCCCR Reporting Manual link.
    [Show full text]
  • Clues for Genetic Anticipation in Multiple Endocrine Neoplasia Type 1
    Copyedited by: oup CLINICAL RESEARCH ARTICLE Clues For Genetic Anticipation In Multiple Endocrine Neoplasia Type 1 Downloaded from https://academic.oup.com/jcem/article-abstract/105/7/dgaa257/5836321 by Erasmus Universiteit Rotterdam user on 08 June 2020 Medard F.M. van den Broek,1 Bernadette P.M. van Nesselrooij,2 Carolina R.C. Pieterman,1 Annemarie A. Verrijn Stuart,3 Annenienke C. van de Ven,4 Wouter W. de Herder,5 Olaf M. Dekkers,6 Madeleine L. Drent,7 Bas Havekes,8 Michiel N. Kerstens,9 Peter H. Bisschop,10 and Gerlof D. Valk1 1Department of Endocrine Oncology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; 2Department of Medical Genetics, Wilhelmina Children’s Hospital, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; 3Department of Pediatric Endocrinology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; 4Department of Endocrinology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands; 5Department of Internal Medicine, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands; 6Departments of Endocrinology and Metabolism and Clinical Epidemiology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands; 7Department of Internal Medicine, Section of Endocrinology, Amsterdam UMC, location VU University Medical Center, 1007 MB Amsterdam, The Netherlands; 8Department of Internal Medicine, Division of Endocrinology, Maastricht University Medical Center, 6202 AZ Maastricht, The Netherlands; 9Department of Endocrinology, University Medical Center Groningen, 9700 RB Groningen, The Netherlands; and 10Department of Endocrinology and Metabolism, Amsterdam UMC, location Academic Medical Center, 1100 DD Amsterdam, The Netherlands ORCiD numbers: 0000-0002-4656-2960 (M. F.M. van den Broek); 0000-0002-1333-7580 (O.
    [Show full text]
  • CASE REPORT Uterine Rupture Due to Invasive Metastatic
    UC Irvine Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health Title Uterine Rupture due to Invasive Metastatic Gestational Trophoblastic Neoplasm Permalink https://escholarship.org/uc/item/7064k01v Journal Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health, 14(5) ISSN 1936-900X Authors Bruner, David I Pritchard, Amy M Clarke, Jonathan E Publication Date 2013 DOI 10.5811/westjem.2013.4.15868 License https://creativecommons.org/licenses/by-nc/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California CASE REPORT Uterine Rupture Due to Invasive Metastatic Gestational Trophoblastic Neoplasm David I. Bruner, MD* * Naval Medical Center Portsmouth, Emergency Medicine Program, Portsmouth, Virginia Amy M. Pritchard, DO† † Naval Medical Hospital Camp Pendleton, Oceanside, California Jonathan Clarke, MD‡ ‡ Naval Medical Center Jacksonville, Jacksonville, Florida Supervising Section Editor: Rick McPheetors, DO Submission history: Submitted January 13, 2013; Revision received April 9, 2013; Accepted April 11, 2013 Full text available through open access at http://escholarship.org/uc/uciem_westjem DOI: 10.5811/westjem.2013.4.15868 While complete molar pregnancies are rare, they are wrought with a host of potential complications to include invasive gestational trophoblastic neoplasia. Persistent gestational trophoblastic disease following molar pregnancy is a potentially fatal complication that must be recognized early and treated aggressively for both immediate and long-term recovery. We present the case of a 21-year-old woman with abdominal pain and presyncope 1 month after a molar pregnancy with a subsequent uterine rupture due to invasive gestational trophoblastic neoplasm. We will discuss the complications of molar pregnancies including the risks and management of invasive, metastatic gestational trophoblastic neoplasia.
    [Show full text]
  • The Use of High Tumescent Power Assisted Liposuction in the Treatment of Madelung’S Collar
    Letter to the Editor The use of high tumescent power assisted liposuction in the treatment of Madelung’s collar Henryk Witmanowski1,2, Łukasz Banasiak1, Grzegorz Kierzynka1, Jarosław Markowicz1, Jerzy Kolasiński1, Katarzyna Błochowiak3, Paweł Szychta1,4 1Department of Plastic, Reconstructive and Aesthetic Surgery, Medical College in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland 2Department of Physiology, Poznan University of Medical Sciences, Poznan, Poland 3Department of the Oral Surgery, Poznan University of Medical Sciences, Poznan, Poland 4Department of Oncological Surgery and Breast Diseases, Polish Mother’s Memorial Hospital-Research Institute, Lodz, Poland Adv Dermatol Allergol 2017; XXXIV (4): 366–371 DOI: https://doi.org/10.5114/ada.2017.69319 Mild symmetrical lipomatosis (plural symmetrical The disease most commonly takes a proximal form lipomatosis, multiple symmetric lipomatosis – MSL), which takes the following areas of the body with the fol- also known as Madelung’s disease or Launois-Bensaude lowing frequency: the genial area 92.3%, cervical region syndrome is a rare disease of unknown etiology, first de- 67.7%, shoulder region 54.8%, abdominal 45.2%, chest scribed by Brodie in 1846, Madelung in 1888, and Launois 41.9%, thigh and pelvic rim 32.3% [11, 12]. The periph- with Bensaude in 1898 [1–3]. eral type mainly locates on both sides at the level of the Madelung’s disease incidence is 1 : 250000 [4]. Mul- hands, feet and knees, this is definitely a rarer form of tiple symmetric lipomatosis occurs mainly in the inhabit- the disease. The mixed form is described very rarely. The ants of the Mediterranean area and Eastern Europe, in specified central type is also engaged primarily around males (male to female ratio is 20 : 1), aged 30–70 years, the lower torso, and intermediate parts of the legs.
    [Show full text]
  • Appendix 4 WHO Classification of Soft Tissue Tumours17
    S3.02 The histological type and subtype of the tumour must be documented wherever possible. CS3.02a Accepting the limitations of sampling and with the use of diagnostic common sense, tumour type should be assigned according to the WHO system 17, wherever possible. (See Appendix 4 for full list). CS3.02b If precise tumour typing is not possible, generic descriptions to describe the tumour may be useful (eg myxoid, pleomorphic, spindle cell, round cell etc), together with the growth pattern (eg fascicular, sheet-like, storiform etc). (See G3.01). CS3.02c If the reporting pathologist is unfamiliar or lacks confidence with the myriad possible diagnoses, then at this point a decision to send the case away without delay for an expert opinion would be the most sensible option. Referral to the pathologist at the nearest Regional Sarcoma Service would be appropriate in the first instance. Further International Pathology Review may then be obtained by the treating Regional Sarcoma Multidisciplinary Team if required. Adequate review will require submission of full clinical and imaging information as well as histological sections and paraffin block material. Appendix 4 WHO classification of soft tissue tumours17 ADIPOCYTIC TUMOURS Benign Lipoma 8850/0* Lipomatosis 8850/0 Lipomatosis of nerve 8850/0 Lipoblastoma / Lipoblastomatosis 8881/0 Angiolipoma 8861/0 Myolipoma 8890/0 Chondroid lipoma 8862/0 Extrarenal angiomyolipoma 8860/0 Extra-adrenal myelolipoma 8870/0 Spindle cell/ 8857/0 Pleomorphic lipoma 8854/0 Hibernoma 8880/0 Intermediate (locally
    [Show full text]
  • Chapter 05- Mental, Behavioral and Neurodevelopmental Disorders
    Chapter 5 Mental, Behavioral and Neurodevelopmental disorders (F01-F99) Includes: disorders of psychological development Excludes2: symptoms, signs and abnormal clinical laboratory findings, not elsewhere classified (R00-R99) This chapter contains the following blocks: F01-F09 Mental disorders due to known physiological conditions F10-F19 Mental and behavioral disorders due to psychoactive substance use F20-F29 Schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders F30-F39 Mood [affective] disorders F40-F48 Anxiety, dissociative, stress-related, somatoform and other nonpsychotic mental disorders F50-F59 Behavioral syndromes associated with physiological disturbances and physical factors F60-F69 Disorders of adult personality and behavior F70-F79 Intellectual disabilities F80-F89 Pervasive and specific developmental disorders F90-F98 Behavioral and emotional disorders with onset usually occurring in childhood and adolescence F99 Unspecified mental disorder Mental disorders due to known physiological conditions (F01-F09) Note: This block comprises a range of mental disorders grouped together on the basis of their having in common a demonstrable etiology in cerebral disease, brain injury, or other insult leading to cerebral dysfunction. The dysfunction may be primary, as in diseases, injuries, and insults that affect the brain directly and selectively; or secondary, as in systemic diseases and disorders that attack the brain only as one of the multiple organs or systems of the body that are involved. F01 Vascular dementia
    [Show full text]
  • New Management of Gestational Trophoblastic Diseases; a Continuum of Moles to Choriocarcinoma: a Review Article
    ©2018 ASP Ins., Afarand Scholarly Publishing Institute, Iran ISSN: 2476-5848; Journal of Obstetrics, Gynecology and Cancer Research. 2018;3(3):123-128. New Management of Gestational trophoblastic diseases; A Continuum of Moles to Choriocarcinoma: A Review Article A R T I C L E I N F O A B S T R A C T Introduction Article Type Gestational trophoblastic diseases (GTD) is the only group of female reproductive neoplasms derived from paternal genetic material (Androgenic origin). GTD Analytical Review Authors is a continuum from benign to malignant; molar pregnancy is benign, but choriocarcinoma 1 MD is malignant. Approximately 45% of patients have metastatic disease when Gestational 1 MD trophoblastic neoplasia (GTN) is diagnosed. GTN is unique in women malignancies because 2 Soheila Aminimoghaddam* MD, PhD it arises from trophoblast but not from genital organs. It is curable with chemotherapy, Nastaran Abolghasem , Tahereh Ashraf- Ganjooie , low-risk GTN completely response to single-agent chemotherapy and does not require Conclusionhistological confirmation. In persistent GTN, clinical staging and workup of metastasis should be performed. The aim of the present study was to review the new management of GTD. In the case of brain, liver, or renal metastases, any woman of reproductive age How to cite this article who presents with an apparent metastatic malignancy of unknown primary site should be screened for the possibility of GTN with a serum HCG level. Excisional biopsy is not indicated to histologically confirm the diagnosis of malignant GTN if the patient is not pregnant and Soheila Aminimoghaddam, Nas- taran Abolghasem, Tahereh As-hraf- has a high HCG value.
    [Show full text]
  • Pathology and Genetics of Tumours of Soft Tissue and Bone
    bb5_1.qxd 13.9.2006 14:05 Page 3 World Health Organization Classification of Tumours WHO OMS International Agency for Research on Cancer (IARC) Pathology and Genetics of Tumours of Soft Tissue and Bone Edited by Christopher D.M. Fletcher K. Krishnan Unni Fredrik Mertens IARCPress Lyon, 2002 bb5_1.qxd 13.9.2006 14:05 Page 4 World Health Organization Classification of Tumours Series Editors Paul Kleihues, M.D. Leslie H. Sobin, M.D. Pathology and Genetics of Tumours of Soft Tissue and Bone Editors Christopher D.M. Fletcher, M.D. K. Krishnan Unni, M.D. Fredrik Mertens, M.D. Coordinating Editor Wojciech Biernat, M.D. Layout Lauren A. Hunter Illustrations Lauren A. Hunter Georges Mollon Printed by LIPS 69009 Lyon, France Publisher IARCPress International Agency for Research on Cancer (IARC) 69008 Lyon, France bb5_1.qxd 13.9.2006 14:05 Page 5 This volume was produced in collaboration with the International Academy of Pathology (IAP) The WHO Classification of Tumours of Soft Tissue and Bone presented in this book reflects the views of a Working Group that convened for an Editorial and Consensus Conference in Lyon, France, April 24-28, 2002. Members of the Working Group are indicated in the List of Contributors on page 369. bb5_1.qxd 22.9.2006 9:03 Page 6 Published by IARC Press, International Agency for Research on Cancer, 150 cours Albert Thomas, F-69008 Lyon, France © International Agency for Research on Cancer, 2002, reprinted 2006 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention.
    [Show full text]
  • Nesidioblastosis in the Adult: a Case Report
    Cirugía y Cirujanos. 2015;83(4):324---328 CIRUGÍA y CIRUJANOS Órgano de difusión científica de la Academia Mexicana de Cirugía Fundada en 1933 www.amc.org.mx www.elsevier.es/circir CLINICAL CASE ଝ Nesidioblastosis in the adult: A case report a,∗ a Luis Ricardo Ramírez-González , Jorge Arturo Sotelo-Álvarez , b c b Priscila Rojas-Rubio , Michel Dassaejv Macías-Amezcua , Rafael Orozco-Rubio , c Clotilde Fuentes-Orozco a Departamento de Cirugía General, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México b Departamento de Endocrinología, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México c Unidad de Investigación en Epidemiología Clínica, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México Received 3 July 2014; accepted 21 August 2014 KEYWORDS Abstract Nesidioblastosis; Background: Nesidioblastosis is a rare cause of endocrine disease which represents between Adult; 0.5% and 5% of cases. This has been associated with other conditions, such as in patients previ- Hyperinsulinaemic ously treated with insulin or sulfonylurea, in anti-tumour activity in pancreatic tissue of patients hypoglycaemias with insulinoma, and in patients with other tumours of the Langerhans islet cells. In adults it is presented as a diffuse dysfunction of ␤ cells of unknown cause. Clinical case: The case concerns 46 year-old female, with a history of Sheehan syndrome of fifteen years of onset, and with repeated events characterised with hypoglycaemia in the last three years.
    [Show full text]
  • Treatment Strategies for Well-Differentiated Liposarcomas and Therapeutic Outcomes
    ANTICANCER RESEARCH 32: 1821-1826 (2012) Treatment Strategies for Well-differentiated Liposarcomas and Therapeutic Outcomes NORIO YAMAMOTO1, KATSUHIRO HAYASHI1, YOSHIKAZU TANZAWA1, HIROAKI KIMURA1, AKIHIKO TAKEUCHI1, KENTARO IGARASHI1, HIROYUKI INATANI1, SHINGO SHIMOZAKI1, SEIKO KITAMURA2 and HIROYUKI TSUCHIYA1 1Department of Orthopedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan; 2Department of Pathology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan Abstract. This study examined 45 patients with well- liposarcoma tends to be less than the one performed in differentiated liposarcoma who were surgically treated at our conventional extensive resection (7, 8). However, operative hospital (initial surgery in 41 patients and reoperation in 4). procedures from marginal resection to extensive resection Only one patient had recurrence among patients who vary among institutions. In this study, we examined the underwent initial surgery, and the recurrence was localised outcomes of well-differentiated liposarcomas treated at our in the retroperitoneal space. For patients who underwent hospital and we discuss future treatment strategies. reoperation, the mean time between the initial surgery and the recurrence was 16.5 years. None of the 45 patients Patients and Methods developed distant metastasis. It is important to preserve not only neurovascular bundles but also lower limb muscles in The subjects of this study were 45 patients with well-differentiated order to maintain ambulatory ability in the elderly patients. liposarcomas who were surgically treated in our hospital between For well-differentiated liposarcomas of the limbs, it is January 1989 and July 2010 and who were followed-up for at least 6 months. The study group consisted of 17 men and 28 women.
    [Show full text]
  • The ICD-10 Classification of Mental and Behavioural Disorders : Clinical Descriptions and Diagnostic Guidelines
    ICD-10 ThelCD-10 Classification of Mental and Behavioural Disorders Clinical descriptions and diagnostic guidelines | World Health Organization I Geneva I 1992 Reprinted 1993, 1994, 1995, 1998, 2000, 2002, 2004 WHO Library Cataloguing in Publication Data The ICD-10 classification of mental and behavioural disorders : clinical descriptions and diagnostic guidelines. 1.Mental disorders — classification 2.Mental disorders — diagnosis ISBN 92 4 154422 8 (NLM Classification: WM 15) © World Health Organization 1992 All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications — whether for sale or for noncommercial distribution — should be addressed to Publications, at the above address (fax: +41 22 791 4806; email: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]